David A. Siegel Novo Cure LTD Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Novo Cure LTD stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,319,400 shares of NVCR stock, worth $23.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,319,400

Previous 1,438,900 8.3%

Holding current value

$23.3 Million

Previous $22.5 Million 0.49%

% of portfolio

0.05%

Previous 0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $1.41 Million - $2.87 Million	-119,500 Reduced 8.3%	1,319,400 $22.6 Million
Q1 2024 May 15, 2024	SELL	$12.42 - $17.29 $2.43 Million - $3.38 Million	-195,600 Reduced 11.97%	1,438,900 $22.5 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $7.93 Million - $11.2 Million	712,100 Added 77.2%	1,634,500 $24.4 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $13.8 Million - $36.1 Million	851,800 Added 1206.52%	922,400 $14.9 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $584,205 - $1.2 Million	14,500 Added 25.85%	70,600 $2.93 Million
Q1 2023 May 15, 2023	SELL	$56.44 - $118.81 $4.84 Million - $10.2 Million	-85,800 Reduced 60.47%	56,100 $3.37 Million
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $2.55 Million - $3.41 Million	-39,900 Reduced 21.95%	141,900 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $1.99 Million - $2.62 Million	-29,300 Reduced 13.88%	181,800 $13.8 Million
Q2 2022 Aug 15, 2022	SELL	$56.6 - $89.9 $3.24 Million - $5.14 Million	-57,200 Reduced 21.32%	211,100 $14.7 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $2.1 Million - $2.95 Million	-34,900 Reduced 11.51%	268,300 $22.2 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $1.76 Million - $2.87 Million	-23,500 Reduced 7.19%	303,200 $22.8 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $1.32 Million - $2.22 Million	11,400 Added 3.62%	326,700 $38 Million
Q2 2021 Aug 16, 2021	SELL	$130.4 - $225.58 $17.8 Million - $30.8 Million	-136,600 Reduced 30.23%	315,300 $69.9 Million
Q1 2021 May 17, 2021	SELL	$124.11 - $190.17 $3.6 Million - $5.51 Million	-29,000 Reduced 6.03%	451,900 $59.7 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $19.4 Million - $30.1 Million	-172,800 Reduced 26.43%	480,900 $83.2 Million
Q3 2020 Nov 16, 2020	SELL	$58.05 - $111.31 $13.5 Million - $25.8 Million	-231,800 Reduced 26.18%	653,700 $72.8 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $15 Million - $19.5 Million	262,100 Added 42.04%	885,500 $52.5 Million
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $15.4 Million - $25.8 Million	-269,900 Reduced 30.21%	623,400 $42 Million
Q4 2019 Feb 14, 2020	SELL	$68.3 - $93.8 $81,960 - $112,560	-1,200 Reduced 0.13%	893,300 $75.3 Million
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $17.5 Million - $27.6 Million	282,200 Added 46.09%	894,500 $66.9 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $3.42 Million - $5.12 Million	81,000 Added 15.25%	612,300 $38.7 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $9.13 Million - $16 Million	285,800 Added 116.42%	531,300 $25.6 Million
Q4 2018 Feb 14, 2019	SELL	$28.72 - $52.63 $3.37 Million - $6.17 Million	-117,300 Reduced 32.33%	245,500 $8.22 Million
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $3.72 Million - $6.09 Million	116,300 Added 47.18%	362,800 $19 Million
Q2 2018 Aug 14, 2018	BUY	$19.85 - $32.0 $4.27 Million - $6.89 Million	215,300 Added 690.06%	246,500 $7.72 Million
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $400,494 - $490,761	20,751 Added 198.59%	31,200 $680,000
Q4 2017 Feb 14, 2018	BUY	$16.3 - $21.9 $170,318 - $228,833	10,449	10,449 $211,000

Others Institutions Holding NVCR

# of Institutions

264

Shares Held

78.6M

Call Options Held

751K

Put Options Held

293K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.85B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account